Abel Hall LLC Acquires Shares of 13,049 GSK plc (NYSE:GSK)

Abel Hall LLC acquired a new stake in GSK plc (NYSE:GSK) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 13,049 shares of the pharmaceutical company’s stock, valued at approximately $484,000.

Several other hedge funds also recently bought and sold shares of GSK. Hsbc Holdings PLC bought a new position in shares of GSK during the 4th quarter worth $92,281,000. Armistice Capital LLC grew its position in shares of GSK by 670.5% during the 4th quarter. Armistice Capital LLC now owns 2,196,000 shares of the pharmaceutical company’s stock worth $81,384,000 after buying an additional 1,911,000 shares in the last quarter. Fisher Asset Management LLC grew its position in shares of GSK by 10.8% during the 4th quarter. Fisher Asset Management LLC now owns 15,065,558 shares of the pharmaceutical company’s stock worth $558,330,000 after buying an additional 1,465,165 shares in the last quarter. Provident Trust Co. grew its position in shares of GSK by 53.6% during the 4th quarter. Provident Trust Co. now owns 3,716,830 shares of the pharmaceutical company’s stock worth $137,746,000 after buying an additional 1,297,385 shares in the last quarter. Finally, FMR LLC grew its position in shares of GSK by 7.7% during the 3rd quarter. FMR LLC now owns 18,099,513 shares of the pharmaceutical company’s stock worth $656,107,000 after buying an additional 1,291,161 shares in the last quarter. Institutional investors own 15.74% of the company’s stock.

GSK Stock Down 1.1 %

Shares of NYSE GSK traded down $0.46 during mid-day trading on Friday, reaching $40.65. 2,235,352 shares of the company were exchanged, compared to its average volume of 3,880,191. The company has a quick ratio of 0.58, a current ratio of 0.87 and a debt-to-equity ratio of 1.15. The stock has a market cap of $84.24 billion, a price-to-earnings ratio of 14.73, a P/E/G ratio of 1.23 and a beta of 0.66. GSK plc has a 1 year low of $33.67 and a 1 year high of $45.92. The firm has a 50-day moving average of $42.56 and a 200 day moving average of $40.93.

GSK (NYSE:GSK) last issued its quarterly earnings data on Wednesday, May 1st. The pharmaceutical company reported $1.09 earnings per share for the quarter, topping analysts’ consensus estimates of $0.94 by $0.15. GSK had a return on equity of 51.54% and a net margin of 14.62%. The firm had revenue of $9.34 billion during the quarter, compared to analysts’ expectations of $8.98 billion. On average, research analysts expect that GSK plc will post 4.11 earnings per share for the current year.

GSK Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, July 11th. Shareholders of record on Friday, May 17th will be paid a $0.3762 dividend. The ex-dividend date is Thursday, May 16th. This is a boost from GSK’s previous quarterly dividend of $0.36. This represents a $1.50 dividend on an annualized basis and a yield of 3.70%. GSK’s dividend payout ratio (DPR) is 53.26%.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on the company. Guggenheim raised GSK from a “neutral” rating to a “buy” rating in a research report on Monday, March 4th. The Goldman Sachs Group assumed coverage on GSK in a research note on Thursday, May 30th. They set a “neutral” rating and a $47.00 price objective for the company. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $47.00.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.